Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY:LLY)

769.88 +4.20 (+0.55%)
Official Closing Price Updated: 7:00 PM EDT, Jun 6, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2
...
20 21 22 23 24 25 26 27 28
...
99 100 Next >
Could Eli Lilly Beat Rivals in the Billion-Dollar Weight Loss Drug Market in 2025? Evidence Is Piling Up, and Here's What It Says.
Via The Motley Fool
Eli Lilly Stock Price Analysis – Earnings Miss And The Pullback Worth Watching
The company lowered its FY2024 guidance following Q3 earnings, citing supply chain challenges for top-selling drugs like Mounjaro and Zepbound and a one-time R&D expense from its $3.2 billion... 
Via Talk Markets
Topics Earnings Economy Stocks / Equities
Exposures Financial Supply Chain
Eli Lilly Investments In Production Reach $23 Billion With Additional $3 Billion Expansion At US Facility
Eli Lilly plans a $3 billion expansion of its Wisconsin facility, creating 750 skilled jobs and boosting production capacity for critical medicines with advanced automation. 
Via Benzinga
Alzheimer’s Disease Therapy Provides Patients With Hope
(BPT) - (In Partnership with Eli Lilly and Company) 
Via Brandpoint
Stock Market Hits Highs On Salesforce, Tech Earnings; Bitcoin Tops $100,000, Briefly: Weekly Review
Salesforce and mostly positive tech earnings buoyed the major indexes. 
Via Investor's Business Daily
Are you living with eczema? It's time to get the care you deserve
(BPT) - Sponsored by Eli Lilly and Company 
Via Brandpoint
Amgen Stock Falls on Weight Loss Drug Data: Overreaction or Fair?
Results for Amgen's weight loss drug Maritide were highly anticipated, but fell short. However, MariTide could still turn the tables in future studies. 
Via MarketBeat
Billionaire Izzy Englander Is Buying This Obesity Drug Stock That Could Soar Nearly 20%, According to Wall Street
Via The Motley Fool
How Much Did Americans Overspend On Weight Loss Medications in 2024? GoodRx Reveals
GoodRx's latest research shows surging demand for weight loss medications like Wegovy and Zepbound, despite high costs and limited insurance coverage, with consumers overspending $200 million in 2024. 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
2 Telehealth Stocks That Could Gain from Trump’s New FDA Pick
Discover two telehealth stocks, Hims & Hers (HIMS) and Teladoc (TDOC), poised to benefit from Trump's FDA nominee, Dr. Marty Makary, a telemedicine advocate. 
Via MarketBeat
Topics Government Lawsuit
Exposures Financial Legal Political
Decoding Eli Lilly's Options Activity: What's the Big Picture?
Via Benzinga
The Weight-Loss Battle That Could Rattle Eli Lilly's $100 Billion Market
An age-old battle in pharmaceuticals could further rattle Eli Lilly stock and its potential $100 billion market in obesity. 
Via Investor's Business Daily
This Healthcare Stock Is a Favorite of Billionaires. But Is It a Buy?
Unsurprisingly, these stock pickers are capitalizing on an opportunity that's only recently become addressable. 
Via The Motley Fool
Lilly Tops Nordisk In Weight Loss Battle
The two market-leading weight loss/obesity drugs (GLP-1), Zepabound (Eli Lilly) and Wegovy (Novo Nordisk), just completed a clinical side-by-side trial. 
Via Talk Markets
Topics Stocks / Equities
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Stock Of The Day: Where Will The Eli Lilly Rally End?
Shares of Eli Lilly (LLY) are approaching a price level that had previously been a peak. There is a good chance they hit resistance at it. 
Via Benzinga
Eli Lilly Stock Hits 3-Week High, Boosts Retail Mood On Zepbound’s Edge Over Wegovy In Weight-Loss Trial Showdown
Participants lost an average of 20.2% body weight on Zepbound versus 13.7% on Wegovy over 72 weeks. 
Via Stocktwits
Eli Lilly's Zepbound Vs. Novo Nordisk's Wegovy - Which Shows Greater Weight Loss?
Eli Lilly's Zepbound outperformed Wegovy in weight loss and key outcomes during the SURMOUNT-5 trial, showing a comparable safety profile. 
Via Benzinga
Jim Cramer: This Energy Stock Is A 'Winner,' But Navitas Semiconductor Is 'Losing A Lot Of Money'
Navitas Semiconductor is losing money according to Jim Cramer. LandBridge Company is a winner, while Regeneron is facing sales challenges. 
Via Benzinga
Eli Lilly's Zepbound Beats Novo Nordisk's Wegovy In Head-To-Head Weight-Loss Trial
Lilly touted findings from the first head-to-head clinical trial. 
Via Investor's Business Daily
Eli Lilly Just Got a Bundle of Good News: Time to Buy?
Via The Motley Fool
Weight Loss Drug Wars Heat Up: Amgen Challenges Eli Lilly, Novo's Dominance
Amgen's new obesity drug, MariTide, shows promise against giants Eli Lilly and Novo Nordisk, but faces tough competition in a $100B market. 
Via Benzinga
Want To Bet On Ozempic, Wegovy Success? Defiance Introduces Leveraged ETF To Capture Novo Nordisk Momentum
Defiance ETFs introduces NVOX, a leveraged ETF offering 2X exposure to Novo Nordisk's stock price movements, targeting the booming weight loss market with tactical trading opportunities. 
Via Benzinga
Topics ETFs
Eli Lilly Gap
I took on a bearish position on Eli Lilly (LLY​​​​​​​) today. I think the days of Big Pharma just printing up profits out of thin air are over. 
Via Talk Markets
Topics Stocks / Equities
It’s Been A Tough Month For Healthcare Stocks
It’s been a very difficult month for the healthcare sector not only because of disappointing company news but also disruption caused by the election and future policy issues. 
Via Talk Markets
Topics ETFs Stocks / Equities
Macy's Multimillion-Dollar Error
We also talk about snack foods, AI, Netflix's strategy on live events, and more. 
Via The Motley Fool
Topics Artificial Intelligence
Exposures Artificial Intelligence
Big Pharma Pushes To Revise Biden-era Medicare Drug Price Negotiation Law Under Trump
Pharma companies lobby for changes to Medicare drug price rules, targeting a four-year delay for pills' eligibility. Critics warn it may hinder patient access and innovation. 
Via Benzinga
Weight Loss Drugs Like Wegovy, Zepbound Linked To Reduced Alcohol Use: Study
A study finds that anti-obesity medications may help reduce alcohol consumption, with nearly half of participants in weight loss programs reporting decreased use. 
Via Benzinga
Prediction: This Unstoppable Vanguard ETF Will Beat the S&P 500 Again in 2025
This exchange-traded fund holds big positions in top-performing growth stocks like Nvidia. 
Via The Motley Fool
Topics ETFs Stocks
Exposures US Equities
< Previous 1 2
...
20 21 22 23 24 25 26 27 28
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.